Utility of lncRNAs as Predictive Markers for Immune Checkpoint Inhibitor Therapy in Renal Cancer. Homo sapiens

The study aims to identify and validate long non-coding RNAs (lncRNAs) as predictive biomarkers for immune checkpoint inhibitor (ICI) therapy in renal cancer, specifically clear cell renal cell carcinoma (ccRCC). This research is relevant as it seeks to improve the effectiveness of ICI therapy by identifying patients who are more likely to benefit from the treatment, thereby optimizing personalized medicine strategies and potentially improving patient outcomes.